TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis

07:00 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis Positive Phase 2 study results with THVD-102, an orally administered combination drug product for the treatment of primary focal hyperhid...

Other Sources for this Article

TheraVida, Inc.
Ben McGraw, +1 650-638-2335


More From BioPortfolio on "TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...